Diagnostic, prognostic and predictive values of miR-100 and miR-210 in pediatric acute lymphoblastic Leukemia

Figures & data

Table 1. Clinico-pathological features of pediatric ALL patients.

Patients’ characteristics	Frequency (%)
Age
Mean ± SD	7.6 ± 5.07 years
Median (range)	6 (1–17) years
Sex
Male	47 (55.3%)
Female	38 (44.7%)
TLC (median and range)×10^9/L	19.4 (1.47–714.6)
HB (median and range) g/dL	8.1 (3.5–14.9)
PLT (median and range) ×10^9/L	49 (4–723)
BP blast (median and range) %	65 (0–98)
BM blast (median and range) %	91 (26–99)
BM cellularity
hypercelluar	71 (83.5%)
normocelluar	11 (12.9%)
hypocelluar	3 (3.5%)
Immunophenotyping (IPT)
T	18 (21.2%)
B (C-ALL)	17 (20.0%)
B (pre-B)	50 (58.8%)
Karyotyping
normal	68 (80.9%)
abnormal	16 (19.1%)
Risk
LR	33 (38.8%)
SR	45 (52.9%)
HR	7 (8.2%)
MRD D15
<0.01%	40 (47.1%)
≥0.01%	24 (28.2%)
NA	21 (24.7%)
MRD D42
<0.01%	50 (58.8%)
≥0.01%	17 (20.0%)
NA	18 (21.2%)
Morphological response(day 15)
CR	63 (85.1%)
No CR	11 (14.8%)
Morphological response (day 42)
CR	67 (98.5%)
No CR	1 (1.5%)
Organomegaly
Noorganomegaly	22 (25.9%)
hepatomegaly	14 (16.5%)
splenomegaly	7 (8.2%)
HSM	42 (49.4%)
Lymphadenopathy
−ve	31 (36.5%)
+ve	54 (63.5%)
Survival
Early death	9 (10.7%)
late death	10 (11.9%)
alive	65 (77.4%)

Figure 1. Expression levels of: (A) miR-100 and (B) miR-210 in BM aspirate of pediatric ALL patients compared to normal controls. ROC analysis of (C) miR-100 and (D) miR-210 for the diagnosis of pediatric ALL patients.

Table 2. ROC analysis for diagnosis of pediatric ALL with miRNA-210 and miRNA-100.

Marker	AUC	Cutoff	Sensitivity	Specificity	P value	SE	95% CI
miR 100	0.642	2.6	64.7%	62.5%	0.035	0.062	0.519–0.764
miR 210	0.650	3.5	60%	58.3%	0.025	0.071	0.511–0.790

Table 3. Association between miRNA 210, miRNA 100 and patients’ characteristics.

	miR-210		P value	miR-100		P value
	Low-expression	overexpression		Low-expression	Overexpression
Age
≤2 years	2 (5.9%)	10 (19.6%)	0.112	7 (12.5%)	5 (17.2%)	0.533
>2years	32 (94.1%)	41 (80.4%)		49 (87.5%)	24 (82.8%)
TLC median(range)	27.8 (1.47–714.6)	17.3 (1.9–348.7)	0.099	26 (1.5–524.9)	12.9 (1.9–714.6)	0.204
Hb median (range)	8.9 (4.2–14.9)	8 (3.5–13.1)	0.569	7.8 (4.2–14.9)	7.8 (3.5–12.3)	0.42
PLT median (range)	51 (10–723)	46 (4–463)	0.238	43.5 (4–723)	56 (5–569)	0.171
PB. Blasts median (range)	61.5 (0–98)	70 (0–96)	0.88	75 (0–98)	55 (0–96)	0.054
BM blasts median (range)	90 (40–98)	92 (26–99)	0.078	91 (40–99)	90 (26–98)	0.619
Sex
Male	18 (52.9%)	29 (56.9%)	0.825	35(62.5%)	12 (41.4%)	0.071
Female	16 (47.1%)	22 (43.1%)		21 (37.5%)	17 (58.6%)
BM. cellularity
Hypercelluar	30 (88.2%)	41 (80.4%)	0.622	49 (87.5%)	22 (75.9%)	0.308
Normocelluar	3 (8.8%)	8 (15.7%)		5 (8.9%)	6 (20.7%)
Hypocelluar	1 (2.9%)	2 (3.9%)		2 (3.6%)	1 (3.4%)
IPT
T	12 (35.3%)	6 (11.8%)	0.011	13 (23.2%)	5 (17.2%)	0.012
B(C-ALL)	3 (8.8%)	14 (27.5%)		6 (10.7%)	11 (37.9%)
B (pre-B)	19 (55.9%)	31 (60.8%)		37 (66.1%)	13 (44.8%)
Karyotyping
Normal	26 (78.8%)	42 (82.4%)	0.684	46 (83.6)	22 (75.9%)	0.388
abnormal	7(21.2%)	9 (17.6%)		9 (16.4%)	7 (24.1%)
Organomegaly
No	7 (20.6%)	15 (29.4%)	0.069	14 (25.0%)	8 (27.6%)	0.387
Hepatomegaly	2 (5.9%)	12 (23.5%)		7 (12.5%)	7 (24.1%)
Splenomegaly	4 (11.8%)	3 (5.9%)		6 (10.7%)	1 (3.4%)
HSM	21 (61.8%)	21 (41.2%)		29 (51.8%)	13 (44.8%)
Lymphadenopathy
−ve	12 (35.3%)	19 (37.3%)	0.991	18 (32.1%)	13 (44.8%)	0.342
+ve	22 (64.7%)	32 (62.7%)		38 (67.9%)	16 (55.2%)
Risk
LR	10 (29.4%)	23 (45.1%)	0.118	21 (37.5%)	12 (41.4%)	0.913
SR	19 (55.9%)	26 (51.0%)		30 (53.6%)	15 (51.7%)
HR	5 (14.7%)	2 (3.9%)		5 (8.9%)	2 (6.9%)
MRD D15
<0.01%	20 (71.4%)	20 (55.6%)	0.298	28 (65.1%)	12 (57.1%)	0.589
≥0.01%	8 (28.6%)	16 (44.4%)		15 (34.9%)	9 (42.9%)
MRD D42
<0.01%	22 (75.9%)	28 (73.7%)	0.839	35 (77.8%)	15 (68.2%)	0.551
≥0.01%	7 (24.1%)	10 (26.3%)		10 (22.2%)	7 (31.8%)

Figure 2. Association between (A) miR-210, (B) miR-100 and MRD of the assessed pediatric ALL patients.

Figure 3. Association between (A) miR-100, (B) miR-210 expression and DFS rates of the ALL patients.

Figure 4. Association between miR-100 expression and: (A) overall survival (OS) rates, (B) incidence of early death, (C) incidence of late death. Association between miR-210 expression and: (D) overall survival (OS) rates, (E) incidence of early death, (F) incidence of late death.